Zimmer Biomet (ZBH) Projected to Post Quarterly Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) is expected to be issuing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of $1.87 per share and revenue of $2.0089 billion for the quarter. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company’s revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 EPS. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $99.86 on Tuesday. The company has a market cap of $19.78 billion, a P/E ratio of 24.30, a PEG ratio of 2.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet has a one year low of $89.22 and a one year high of $114.72. The business’s 50-day simple moving average is $101.30 and its 200 day simple moving average is $97.64.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Analysts Set New Price Targets

Several equities research analysts recently commented on ZBH shares. Royal Bank Of Canada set a $111.00 target price on Zimmer Biomet in a report on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Raymond James Financial raised their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Rothschild & Co Redburn began coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective on the stock. Finally, Canaccord Genuity Group restated a “hold” rating and set a $101.00 price objective on shares of Zimmer Biomet in a report on Wednesday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $111.94.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Orion Porfolio Solutions LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $426,000. State of Wyoming acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $124,000. Headlands Technologies LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $37,000. Corient Private Wealth LLC grew its position in shares of Zimmer Biomet by 78.8% in the 2nd quarter. Corient Private Wealth LLC now owns 105,077 shares of the medical equipment provider’s stock worth $9,585,000 after acquiring an additional 46,317 shares in the last quarter. Finally, Chapman Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $218,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.